Bmab 1400 (Denosumab biosimilar)
Osteoporosis, Bone Metastasis
Key Facts
About Biocon
Biocon's mission is to deliver affordable, high-quality biopharmaceuticals to a global patient population. The company has achieved global leadership in biosimilars, with multiple commercialized products in oncology, immunology, and diabetes, and has built a fully integrated platform from R&D to manufacturing. Its strategy is anchored in leveraging its deep bioprocessing expertise to expand its biosimilar portfolio, advance a pipeline of novel biologics, and grow its contract research and manufacturing services.
View full company profileTherapeutic Areas
Other Osteoporosis, Bone Metastasis Drugs
| Drug | Company | Phase |
|---|---|---|
| Biosimilar Denosumab | Organon (2) | Phase 3 |